Document and Entity Information
Document and Entity Information | Jun. 01, 2022 |
Cover [Abstract] | |
Entity Registrant Name | SOLENO THERAPEUTICS INC |
Amendment Flag | true |
Entity Central Index Key | 0001484565 |
Document Type | 8-K/A |
Document Period End Date | Jun. 01, 2022 |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36593 |
Entity Tax Identification Number | 77-0523891 |
Entity Address, Address Line One | 203 Redwood Shores Pkwy |
Entity Address, Address Line Two | Suite 500 |
Entity Address, City or Town | Redwood City |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94065 |
City Area Code | (650) |
Local Phone Number | 213-8444 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.001 par value |
Trading Symbol | SLNO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | This Current Report on Form 8-K/A (the “Amendment”) is being filed as an amendment to the Current Report on Form 8-K filed by Soleno Therapeutics, Inc. (the “Company”) on June 3, 2022 (the “Original Report”). The Original Report was filed with the Securities and Exchange Commission to report the results of the matters submitted to a vote by the Company’s stockholders at the Company’s 2022 Annual Meeting of Stockholders held on June 1, 2022 (the “2022 Annual Meeting”). The sole purpose of this Amendment is to disclose, in accordance with Item 5.07(d) of Form 8-K, the Company’s decision as to how frequently the Company will conduct future stockholder advisory votes regarding named executive compensation. |